Concepedia

Author

Douglas M. Potter

UPMC Hillman Cancer Center

Also Known As

D M Potter, DOUGLAS M. POTTER, Douglas M Potter, Douglas M. Potter, Douglas Potter, Potter, Douglas

111

Publications

4.9K

Citations

39

H-Index

119

Concepts

All Affiliations

UPMC Hillman Cancer CenterUniversity of PittsburghNeurological SurgeryUniversity of Pittsburgh Medical CenterNational Cancer Institute
DM

About

Douglas M. Potter is an author at UPMC Hillman Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

29

1.5K

2

Health Sciences

4

4

96

3

Engineering

2

2

43

4

Public Health

2

2

51

5

Social Sciences

1

1

43

Douglas M. Potter

×

57

Publications

4.4K

Citations

37

H-Index

YearCitations

Induction of CD8<sup>+</sup>T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma

Hideho Okada, Paweł Kaliński, Ryo Ueda,

Journal of Clinical Oncology

2010

557

MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study

Takashi Kimura, John McKolanis, Lynda Dzubinski,

Cancer Prevention Research

2012

257

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides

Lisa H. Butterfield, Antoni Ribas, Vivian B. Dissette,

Clinical Cancer Research

2006

230

Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas

Ian F. Pollack, Regina I. Jakacki, Lisa H. Butterfield,

Journal of Clinical Oncology

2014

201

Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies

Suresh S. Ramalingam, Robert A. Parise, Ramesh K. Ramananthan,

Clinical Cancer Research

2007

196

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients with Refractory Advanced Cancers

Ramesh K. Ramanathan, Donald L. Trump, Julie L. Eiseman,

Clinical Cancer Research

2005

192

Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1

Ryo Ueda, Gary Kohanbash, Kotaro Sasaki,

Proceedings of the National Academy of Sciences

2009

175

Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma

William C. Zamboni, Anne Gervais, Merrill J. Egorin,

Cancer Chemotherapy and Pharmacology

2004

163

Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas

Hideho Okada, Frank S. Lieberman, Kevin A. Walter,

Journal of Translational Medicine

2007

128

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

Lisa H. Butterfield, Begonya Comin-Anduix, Lazar Vujanović,

Journal of Immunotherapy

2008

120

Page 1